Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
32actual
Sites
12
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-27 | actual | When the study began enrolling |
| Primary completion | 2025-03-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-10 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-16 | actual | When this record first appeared on the registry |
| Results posted | 2026-04-15 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Extensive Stage Small Cell Lung Cancer
Intervention
- Drug: Tarlatamab — also filed as AMG 757, IMDELLTRA™
Primary outcome
what the primary-completion date above is the date OFObjective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
measured From first dose of trial drug up to a minimum of last dose + 65 days or data cutoff date; median (min, max) time on trial was 3.4 (2.2, 6.5) months at data cut off
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-09-06 · 2.1 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-01-16 · 320 KB · SAP_001.pdf
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed